All In Biotech

Drug Trial Radar · NCT07286032

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

Conditions

  • Patients With Chemotherapy-Induced Thrombocytopenia

Interventions

  • Hetrombopag OlamineDrug

    For Part A, all participants would receive hetrombopag treatment.

  • Hetrombopag Olamine; Hetrombopag Olamine PlaceboDrug

    For Part B, participants would be randomized to receive hetrombopag treatment or matching placebo, respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months.
  2. Part A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months.
  3. Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months.
  4. Part B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.Time frame: around 3 years.
  5. Part B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until the end of the primary treatment period, around 3 years.Time frame: around 3 years.
  6. Part B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years.Time frame: around 3 years.

Locations

51 sites in 11 countries. Site status is shown where the registry gives one.

  • Starling Oncology

    Long Beach, California · Not yet recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • Oncology & Hematology Associates of West Broward

    Coral Springs, Florida · Recruiting

  • Starling Oncology / Oncology Institute of Hope & Innovation

    Miami, Florida · Not yet recruiting

  • Mid-Florida Hematology & Oncology Centers, P.A.

    Orange City, Florida · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi · Not yet recruiting

  • Cancer Partners of Nebraska

    Lincoln, Nebraska · Recruiting

  • Morristown Medical Center

    Morristown, New Jersey · Not yet recruiting

  • MSK Cancer Center

    New York, New York · Not yet recruiting

  • New York Cancer and Blood Specialists One Oncology

    Shirley, New York · Not yet recruiting

  • ARENSIA Exploratory Medicine at "MBAL Sveta Sofia"

    Sofia, Bulgaria · Recruiting

  • UMHAT "Sv. Ivan Rilski", EAD

    Sofia, Bulgaria · Not yet recruiting

  • Hong Kong United Oncology Centre

    Hong Kong, Hong Kong, China · Not yet recruiting

  • The Chinese University of Hong Kong

    Hong Kong, Hong Kong, China · Not yet recruiting

  • The University of Hong Kong

    Hong Kong, Hong Kong, China · Not yet recruiting

  • Gustave Roussy Cancer Campus

    Clémont, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Lyon, France · Not yet recruiting

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France · Not yet recruiting

  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari

    Bari, Italy · Not yet recruiting

  • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)

    Milan, Italy · Not yet recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Not yet recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Not yet recruiting

  • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. B. Markiewicza

    Brzozów, Poland · Not yet recruiting

  • Uniwersytecki Szpital Kliniczny w Poznaniu, Klinika Onkologii

    Poznan, Poland · Not yet recruiting

  • Institutul Oncologic Bucuresti Prof Dr. Al. Trestioreanu with SC Arensia Exploratory Medicine

    Bucharest, Romania · Recruiting

  • Institute of Oncology "Ioan Chiricuta" Cluj-Napoca, Arensia Exploratory Medicine

    Cluj-Napoca, Romania · Recruiting

  • Centrul de Oncologie Sfantul Nectarie Craiova

    Craiova, Romania · Not yet recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Not yet recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Pratia ES Sirius Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Reina Sofía Córdoba

    Córdoba, Spain · Not yet recruiting

  • Hospital Universitari Arnau de Vilanova

    Lleida, Spain · Not yet recruiting

  • Hospital Universitario HM Madrid Sanchinarro

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Not yet recruiting

  • Pratia ES Hospital Universitario de Torrejon

    Madrid, Spain · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.